John Flygare
Head of Large Molecule & ADC Innovation Eli Lilly & Co.
John Flygare is Head of Large Molecule and ADC Innovation at Eli Lilly. He has held senior scientific leadership roles across biotech and pharma, has authored/co-authored 100+ publications and patents, and has taught extensively at Stanford University in organic and medicinal chemistry
Seminars
- Engineering conditional activation through masking and pre-dosing in TCEs and ADCs
- Discussing dual-target and multispecific approaches
- Applying induced proximity to ADC specificity to substantially change the behaviour of an ADC
Present your company’s slides by securing a 15-minute presentation slot in front of the
attending audience.
What is this session?
At the intersection of innovative research and business conversations, this forum facilitates the
pitching of biotech pipelines and platforms to attending pharma and investors.
How does this session work?
As you register, secure one of the 15-minute presentation slots available in this presentation
session and position your differentiation as part of the conference line-up. We will add your
talk to this brochure and on our website to showcase your differentiation in the best light and
share your corporate summary with all attendees as part of pre- and post-event content, to drive
interest and follow-up in your session.
Who can present?
Those developing in-house pipeline or platform technology, without any additional service
provider capabilities, such as contract research or manufacturing.
2.00 Presentation by SKYMAB Biotherapeutics
2.15 Presentation by Bicycle Therapeutics
2.30 Presentation by Rapafusyn
- Representing examples of successful deal-making and successful management of alliances to foster future deals, what are the learnings?
- Sharing how early-stage programs can successfully navigate the “show me data” barrier with pharma, and the activation barrier to licencing technologies between equal sized biotech
- Debating recent regulatory and emerging technology shifts, and how these will shape licensing deals for the discussed modalities
